Navigation Links
Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
Date:1/15/2008

nts in a two-stage trial design. Patients with HER2-positive metastatic disease and no prior trastuzumab treatment except as adjuvant therapy (with the last dose more than 12 months prior to study entry) are eligible to participate in the trial. Alvespimycin will be administered intravenously on a one-hour weekly infusion schedule of 80 mg/m2 for three weeks out of four weeks in repeated cycles.

Kosan is also testing alvespimycin delivered orally in a Phase 1 dose escalation trial exploring different schedules.

Promising Antitumor Activity Shown in Phase 1

In September, at the 2007 ASCO Breast Cancer Symposium, Kosan reported that alvespimycin demonstrated promising antitumor activity and tolerability in combination with trastuzumab in a Phase 1 trial of patients with refractory HER2-positive metastatic breast cancer, and in patients with refractory ovarian cancer who were progressing on standard chemotherapy. Of the 27 heavily-pretreated patients enrolled in the Phase 1 trial, 24 patients had HER2-positive metastatic breast cancer and 3 patients had ovarian cancer (HER2 status unknown). Clinical benefit was observed in 42% of patients (8 of 19 evaluable) with HER2-positive metastatic breast cancer. Of the 3 patients with ovarian cancer, 1 patient (13 prior regimens) who was on study for more than 16 months had a near complete resolution of ascites and left pleural effusion, and an 83% decrease in CA125. Toxicities in this Phase 1 trial were mainly Grade 1 and 2 (diarrhea, fatigue, headache, arthralgia, nausea) with 80 mg/m2 established as the recommended Phase 2 dose for weekly intravenous administration. Kosan is currently enrolling a Phase 1 trial to investigate alvespimycin plus trastuzumab and paclitaxel to establish the initial safety profile and pharmacokinetics of this triplet regimen and to lay the groundwork for a potential larger Phase 2/3 trial.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
2. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
3. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
4. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
5. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
6. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
7. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
8. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
9. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
10. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
11. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading ... tissue hypothermic storage and cryopreservation freeze ... management app for smart shippers ("BioLife" or ... has included BioLife in its annual list of the 100 ... for 2015. Now in its 24th ...
(Date:7/2/2015)... China   , July 2, 2015 /PRNewswire/ ... laboratory in Hong Kong has ... BGI Hong Kong facility is the first clinical next-generation-sequencing ... China , meeting the highest standard in clinical ... CFR Part 11 compliant laboratory process, and multiple ISO ...
(Date:7/2/2015)...   Wilson Therapeutics AB , a privately-held biopharmaceutical ... its board of directors. The appointment was approved by ... 30. "We are delighted to welcome Hans ... , CEO of Wilson Therapeutics. "Hans brings significant global ... to his contributions to the Company." Hans ...
Breaking Medicine Technology:BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 3BGI Receives Accreditation from the College of American Pathologists (CAP) 2Wilson Therapeutics Appoints Hans Schikan to its Board of Directors 2
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced the appointment ... Steven A. Elms, the incumbent Chairman and an original venture capital ... Directors after over six years of service. "I want ... the Board as we have grown from an early concept to ...
... Feb. 18, 2011 Tibotec Pharmaceuticals announced today that ... to examine TMC435, its investigational hepatitis C protease inhibitor, ... virus (HCV). A third global phase 3 trial is ... experienced a viral relapse after prior interferon-based treatment. Approximately ...
Cached Medicine Technology:MAP Pharmaceuticals Appoints Scott R. Ward as Chairman of the Board of Directors 2MAP Pharmaceuticals Appoints Scott R. Ward as Chairman of the Board of Directors 3Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV 2Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV 3Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV 4Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV 5
(Date:7/2/2015)... , ... July 02, 2015 , ... The ZAC Foundation, ... 2015 swim season with important lessons on how to stay water safe with the ... Couldn’t, Wouldn’t Swim, authored by The ZAC Foundation co-founders, follows Zeke’s water safety journey. ...
(Date:7/2/2015)... ... July 02, 2015 , ... Healthpointe ... to the orthopedic and spine surgery team at their Anaheim clinic. Dr. Krishnareddy ... tendonitis. Along with the spine and spine surgery, Dr. Krishnareddy also specializes in ...
(Date:7/2/2015)... ... July 02, 2015 , ... Breakthrough technologies are ... treatment. Dr. Lev Kalika, founder of New York Dynamic Neuromuscular Rehabilitation & ... the conservative treatment of back, hip, knee and shoulder pain as well as ...
(Date:7/2/2015)... ... July 02, 2015 , ... eHuman Digital Anatomy, the industry ... their flagship product, 3D Tooth Atlas, version 7.6. This release delivers new and ... videos. This latest release of the 3D Tooth Atlas offers a much faster ...
(Date:7/2/2015)... ... July 02, 2015 , ... After conducting a nationwide executive ... Medical Center in Yuma, Ariz., has hired Robert Trenschel, DO, as chief executive ... management, Dr. Trenschel will assume his new duties at Yuma Regional Medical Center on ...
Breaking Medicine News(10 mins):Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4Health News:eHuman Digital Anatomy Releases 3D Tooth Atlas version 7.6 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3
... Ill., Aug. 3 In the midst of bad economic times, ... devoted efforts of hospital staff and the assistance of a healthcare ... Solutions . While competing hospitals in the area are seeing a ... Center has seen Volume Hours increase 8.5% over the last six months. ...
... , , LARGO, Fla., ... Venture Exchange: UVI) Board of Directors today declared its regular quarterly cash ... stockholders of record at the close of business on August 14, 2009. ... the U.S. $0.09 per share quarterly dividend, which on a annualized dividend ...
... digital mammography equipment alone is responsible for an increased ... facility, according to a study performed at San Luis ... Researchers found that there was a significant increase in ... from film-screen to digital mammography. The number of cancers ...
... international team of researchers has identified a new method ... to new areas for drug development in melanoma ... strategies. Researchers from Virginia Commonwealth University, in collaboration ... Soengas, Ph.D., with the Spanish National Cancer Research Center ...
... ... transitioning to an earlier sleep schedule to avoid losing sleep with an earlier wake time. ... the first day of school. , ... Atlanta, GA (PRWEB) August 3, 2009 -- The lazy days of summer are about ...
... /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), ... Slavica BioChem division have reported results on experiments ... oxygenation (HBO) after traumatic brain injury have been ... doctors from the Hyperbaric Medical Center, School of ...
Cached Medicine News:Health News:Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 2Health News:Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 3Health News:Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 4Health News:Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 5Health News:Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 6Health News:Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 7Health News:Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 8Health News:Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share 2Health News:Parents Lose Sleep Too When Students Begin School, Says Atlanta Sleep Medicine Clinic 2Health News:Parents Lose Sleep Too When Students Begin School, Says Atlanta Sleep Medicine Clinic 3Health News:Parents Lose Sleep Too When Students Begin School, Says Atlanta Sleep Medicine Clinic 4Health News:Parents Lose Sleep Too When Students Begin School, Says Atlanta Sleep Medicine Clinic 5Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 2Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 3Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 4
PT, PTT, Fibrinogetn & TT Normal and Abnormal Controls...
Fructosamine Calibrator...
ApolipoproteinA-1 & B Calibrator...
CRP Full Range (0.1-160mg/l)...
Medicine Products: